7.24
-0.01(-0.14%)
Currency In USD
| Previous Close | 7.25 |
| Open | 7.26 |
| Day High | 7.29 |
| Day Low | 7.03 |
| 52-Week High | 9.76 |
| 52-Week Low | 4.2 |
| Volume | 407,814 |
| Average Volume | 466,562 |
| Market Cap | 391.8M |
| PE | -3.18 |
| EPS | -2.28 |
| Moving Average 50 Days | 7.6 |
| Moving Average 200 Days | 7.78 |
| Change | -0.01 |
If you invested $1000 in Zevra Therapeutics, Inc. (ZVRA) 10 years ago, it would be worth $41.14 as of April 25, 2025 at a share price of $7.24. Whereas If you bought $1000 worth of Zevra Therapeutics, Inc. (ZVRA) shares 5 years ago, it would be worth $1,582.17 as of April 25, 2025 at a share price of $7.24.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism
GlobeNewswire Inc.
Apr 17, 2025 11:30 AM GMT
CELEBRATION, Fla., April 17, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announces the publication
Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
GlobeNewswire Inc.
Apr 07, 2025 11:30 AM GMT
CELEBRATION, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the closing of t
Zevra Therapeutics Files Preliminary Proxy
GlobeNewswire Inc.
Mar 31, 2025 8:12 PM GMT
Confirms Receipt of Two Director Nominees from Daniel J. Mangless Stockholders Are Not Required to Take Action at This Time CELEBRATION, Fla., March 31, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (Nasdaq:GS ZVRA) (“Zevra,” or the “Company”),